Endometrial cancer, originating from the lining of the uterus, represents one of the most common gynecologic malignancies worldwide. While early-stage endometrial cancer often responds well to conventional treatments such as surgery, radiation, and chemotherapy, advanced or recurrent cases, especially those that are mismatch-repair proficient, present substantial therapeutic challenges due to inherent resistance mechanisms. Mismatch-repair proficiency typically correlates with lower mutational burdens and a subdued immune environment, leading to suboptimal responses to immunotherapy alone.

The recent trial, spearheaded by Wu, X., Wang, J., Wang, D., and colleagues, strategically combines fruquintinib—a potent and highly selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor—with sintilimab, a programmed death-1 (PD-1) immune checkpoint inhibitor. This combination exploits both anti-angiogenic and immunomodulatory pathways, hypothesizing that inhibiting tumor vascularization could remodel the tumor microenvironment to enhance immunotherapy efficacy, particularly in pMMR endometrial tumors traditionally less responsive to PD-1 blockade alone.

In this multicenter study, patients with advanced endometrial cancer characterized by mismatch-repair proficiency were enrolled to receive both agents simultaneously. The single-arm design facilitated detailed observation of response rates, safety profiles, and overall tolerability. While the Phase Ib/Ila nature of the study primarily focuses on determining the appropriate dosage and initial efficacy signals, the comprehensive biomarker analyses embedded in the trial design offer pivotal insights into the mechanistic underpinnings of therapeutic response or resistance.

Results from the trial demonstrated a unique synergy between fruquintinib and sintilimab, manifesting in a marked increase in progression-free survival compared to historical controls treated with immunotherapy monotherapy or chemotherapy alone. Notably, a subset of patients displayed partial and complete responses despite the generally immunoresistant phenotype of pMMR tumors. These observations suggest that VEGFR blockade can prime the immune milieu, possibly by normalizing aberrant tumor vasculature and decreasing immunosuppressive cytokines, thereby facilitating enhanced T-cell infiltration and activation.

Mechanistically, fruquintinib’s inhibition of VEGFR1, VEGFR2, and VEGFR3 receptors disrupts angiogenic signaling cascades integral to tumor growth and metastasis. By reducing endothelial proliferation and new blood vessel formation, the tumor’s nutrient and oxygen supply are compromised. This deprivation not only throttles tumor expansion but also alleviates hypoxia-associated immunosuppression. Consequently, sintilimab’s blockade of PD-1 can more effectively reinvigorate exhausted T cells within the tumor microenvironment, unleashing a robust anti-tumor immune response.

The safety profile of this combination was carefully monitored, with treatment-related adverse events consistent with known toxicities of VEGFR inhibitors and immune checkpoint blockade. Hypertension, proteinuria, and fatigue were among the most frequently observed side effects, yet most were manageable with standard supportive care. Importantly, immune-related adverse events did not significantly increase compared to sintilimab monotherapy, underscoring the feasibility of this dual approach for clinical application.

Beyond clinical outcomes, the trial incorporated extensive translational research, including immunophenotyping, genomic sequencing, and angiogenic biomarker assessment. These analyses revealed dynamic changes in the tumor immune landscape post-treatment, characterized by increased infiltration of cytotoxic CD8+ T lymphocytes and decreased levels of immunosuppressive regulatory T cells and myeloid-derived suppressor cells. Moreover, circulating angiogenic factors such as VEGF-A showed significant reduction, correlating with clinical response and supporting the biological rationale for combining anti-angiogenesis with immunotherapy.

The implications of these findings are far-reaching, particularly for tailoring therapeutic strategies in endometrial cancer. Historically, mismatch-repair status has been a critical biomarker guiding the use of immunotherapy, with dMMR (deficient mismatch repair) cancers benefiting more due to higher neoantigen loads. This study challenges the conventional paradigms by demonstrating that even pMMR tumors, generally less immunogenic, can be sensitized through vascular modulation, expanding the pool of patients who might benefit from immune checkpoint inhibition.

These encouraging results warrant further investigation in larger randomized controlled trials to confirm efficacy and elucidate long-term outcomes such as overall survival and quality of life metrics. Additionally, fine-tuning patient selection criteria based on molecular profiling and tumor microenvironment characteristics could optimize personalized treatment regimens, maximizing benefit while minimizing toxicity.

In the evolving landscape of gynecologic oncology, this trial represents a beacon of hope, signaling a paradigm shift toward combinatorial approaches that address multifaceted tumor biology. The integration of targeted anti-angiogenic agents with immunotherapy exemplifies cutting-edge precision medicine, transforming the therapeutic horizon for patients facing advanced, treatment-resistant endometrial cancer.

As ongoing research continues to unravel the complex interplay between tumor vasculature and immune evasion, the success of fruquintinib plus sintilimab may catalyze the development of similar strategies across other malignancies marked by low immunogenicity. Such cross-disciplinary insights could ultimately redefine cancer treatment algorithms, fostering durable remissions and improving survival benchmarks across diverse patient populations.

In summary, the Wu et al. led multicenter Phase Ib/II trial conclusively demonstrates that targeting the VEGFR pathway in conjunction with PD-1 inhibition is a viable and potent therapeutic avenue in mismatch-repair proficient advanced endometrial cancer. By bridging angiogenesis inhibition and immune modulation, this approach surmounts prior therapeutic resistance barriers, heralding a new wave of integrated, rational cancer therapies. This landmark study published in Nature Communications beckons a future where combination regimens grounded in tumor biology offer renewed optimism for patients with historically limited options.

Subject of Research: Advanced endometrial cancer treatment utilizing combination therapy of fruquintinib and sintilimab in mismatch-repair proficient patients.

Article Title: Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.

Article References: Wu, X., Wang, J., Wang, D. et al. Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial. Nat Commun (2025). https://doi.org/10.1038/s41467-025-67375-3

Image Credits: AI Generated

Diffuse pleural mesothelioma is a rare malignancy arising from the mesothelial cells lining the pleura—the protective membrane enveloping the lungs. Globally, approximately 30,000 new cases emerge annually, the vast majority linked to prior asbestos exposure. The disease’s diffuse and infiltrative nature makes it uniquely challenging, often resisting conventional modalities such as surgery, chemotherapy, and radiation therapy. Unlike typical solid tumors, mesotheliomas rarely manifest as discrete masses. Instead, their growth is characterized by a diffuse spreading pattern along the pleural surface, causing difficulties in precise tumor quantification and response assessment using standard imaging techniques.

The clinical trial spearheaded by Dr. Reuss began during his fellowship at the Johns Hopkins Kimmel Cancer Center, where much of the research was conducted. This phase II study evaluated the perioperative administration of nivolumab, a PD-1 immune checkpoint inhibitor, alone or in combination with ipilimumab, a CTLA-4 inhibitor, in patients with surgically resectable diffuse pleural mesothelioma. The main goal was to test the feasibility and safety of neoadjuvant (preoperative) immunotherapy, as well as its integration with subsequent surgical interventions.

Immunotherapy has revolutionized the treatment of various solid tumors by harnessing the body’s immune system to recognize and destroy cancer cells. However, its role in mesothelioma remains understudied and controversial. Prior large-scale trials incorporating surgery with systemic therapies failed to demonstrate consistent survival benefits, casting doubt on the utility of surgical resection. This study challenges that paradigm by incorporating immune checkpoint blockade in a strategic perioperative timeline, attempting to augment antitumor immunity when tumor burden is minimized.

One of the study’s most innovative features lies in its use of circulating tumor DNA (ctDNA) profiling. ctDNA refers to fragments of tumor-derived genetic material released into the bloodstream, offering a minimally invasive biomarker for real-time disease monitoring. Mesothelioma’s low mutational burden complicates traditional ctDNA detection, but the researchers applied an ultra-sensitive genome-wide sequencing approach. This technique enabled the detection of microscopic residual disease that imaging alone could not reveal, providing unprecedented insight into tumor dynamics at a molecular level.

The ability to monitor ctDNA kinetics longitudinally, especially in the perioperative period, may redefine how clinicians assess treatment response. A decrease or absence of ctDNA post-immunotherapy was correlated with better outcomes, while persistence suggested early relapse or treatment resistance. This molecular surveillance could soon guide therapeutic decision-making, tailoring interventions more precisely and potentially sparing patients from ineffective treatments.

Despite these promising findings, the investigators are cautious. Phase II trials primarily assess feasibility, safety, and biological signals rather than definitive clinical efficacy. While both arms of the trial displayed encouraging improvements in progression-free and overall survival, larger randomized studies are necessary to confirm these benefits and elucidate long-term outcomes. This cautious optimism underscores the complexity of mesothelioma and the need for rigorous validation before widespread clinical adoption.

The implications of this research extend beyond just surgical candidacy assessment. By integrating immunotherapy with innovative diagnostic tools, the study illuminates pathways for personalized medicine in a cancer type historically treated with a one-size-fits-all approach. The novel perioperative immunotherapeutic strategy could fundamentally alter the treatment algorithm, shifting the balance toward more individualized and effective interventions.

From a biological standpoint, the diffuse growth pattern of pleural mesothelioma complicates conventional imaging-based response assessments. Tumors often spread thinly along the pleural surfaces, eluding volumetric measurement and confounding radiographic evaluation. The study’s use of ctDNA addresses this limitation, offering a molecular snapshot of tumor presence and burden that complements traditional methods.

The research was supported by a constellation of institutional and governmental grants, with Bristol Myers Squibb sponsoring the clinical trial. Collaborations spanned multiple leading academic cancer centers, reflecting the multidisciplinary effort required to tackle mesothelioma. This collective endeavor highlights the importance of integrating clinical oncology, molecular biology, and bioinformatics to advance cancer therapeutics.

Throughout his commentary on these findings, Dr. Reuss emphasized the potential transformative impact of perioperative immunotherapy but tempered expectations by recognizing the need for continued investigation. “Our study opens windows of opportunity and lays the groundwork for future research to develop better therapies,” he remarked. The road ahead involves larger trials, refinement of ctDNA methodologies, and exploration of combination regimens that can maximize patient outcomes.

In sum, this phase II trial signals an exciting chapter in mesothelioma research, positioning immunotherapy as a pivotal component in the perioperative management of operable diffuse pleural mesothelioma. The integration of cutting-edge molecular diagnostics with innovative treatment strategies paves the way for personalized care models in this challenging disease arena. While the journey toward definitive cure or long-term remission remains arduous, these advances represent critical steps forward, inspiring hope for patients and clinicians alike.

Subject of Research: Diffuse pleural mesothelioma, perioperative immunotherapy, circulating tumor DNA (ctDNA) analyses

Article Title: Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: phase 2 trial results and ctDNA analyses

News Publication Date: September 8, 2025

Web References:

• Nature Medicine Article DOI

References:

• Clinical trial presented at the 2025 World Conference on Lung Cancer, Barcelona, Spain
• Published manuscript in Nature Medicine

Keywords: Cancer, Clinical studies, Diffuse pleural mesothelioma, Immunotherapy, Nivolumab, Ipilimumab, Circulating tumor DNA, ctDNA, Perioperative treatment, Surgical oncology

The clinical trial stems from a critical insight garnered from advanced-stage BTC treatment, where the synergy between immunotherapy and chemotherapy has delivered enhanced survival benefits over chemotherapy alone. Tislelizumab specifically targets the programmed death-1 (PD-1) receptor, a key checkpoint in the immune system that tumors exploit to evade immune surveillance. By blocking PD-1, tislelizumab aims to reinvigorate the patient’s immune response against residual cancer cells after surgery, potentially preventing relapse.

This multicenter, randomized controlled trial is meticulously designed to enroll 140 patients who have undergone curative resection for biliary tract malignancies within the preceding four weeks. Eligible candidates include those diagnosed pathologically with cholangiocarcinoma—whether intrahepatic or extrahepatic—as well as muscle-invasive gallbladder carcinoma. The patient cohort will be randomized evenly to receive either adjuvant capecitabine alone or a combination of capecitabine and tislelizumab, enabling a direct comparison of efficacy and safety parameters.

Recurrence-free survival (RFS) stands as the trial’s primary endpoint, reflecting the pivotal goal of prolonging the period before cancer returns. Secondary endpoints include overall survival (OS), which gauges the ultimate impact on patient longevity, and the incidence and severity of adverse events (AEs), providing a comprehensive view of treatment tolerability. Moreover, the trial integrates exploratory multi-omics analyses to uncover potential biomarkers, offering hope to personalize future treatments based on genetic and molecular tumor profiles.

Adjuvant capecitabine monotherapy has been the backbone of BTC post-surgical treatment, primarily based on studies demonstrating modest survival extensions. However, the immunosuppressive tumor microenvironment and heterogeneity of BTC have limited chemotherapy’s curative potential. Immune checkpoint inhibitors like tislelizumab, which have transformed therapy in other malignancies, present a strategic advancement by modulating host immunity to target micrometastatic disease undetectable by surgery or imaging.

The investigative rationale recognizes that surgical resection alone often fails to eradicate minimal residual disease in BTC, leading to high recurrence rates exceeding 50%. Enhancing the adjuvant approach with immunotherapy may fortify immune surveillance during this critical period, reducing recurrences and improving long-term cure rates. Early-phase studies in advanced BTC hint that PD-1 blockade synergizes with chemotherapy-induced immunogenic cell death, creating a foundation for this trial’s hypothesis.

Designing a study of this caliber involves rigorous protocol elements, ensuring that patient safety remains paramount amid novel drug combinations. Tislelizumab’s safety profile, established in other cancer types, guides dose selection and monitoring. The trial’s integrated biomarker component leverages next-generation sequencing, transcriptomics, and proteomics, aiming to correlate immune gene expression signatures with clinical outcomes—advancing precision oncology.

Patient enrollment and randomization strategies also reflect modern clinical trial standards, from strict inclusion criteria to multicenter collaboration, enhancing the study’s generalizability and statistical power. Outcomes from this trial will provide critical evidence to either endorse or refute adding immunotherapy to the adjuvant treatment of resectable BTC, potentially setting a new standard of care.

The conceptual leap of incorporating immunotherapy into the curative setting is emblematic of broader oncology trends, transitioning immunomodulation from metastatic to earlier disease stages. Given BTC’s historically poor prognosis and limited treatment options, this trial embodies an urgent exploration of innovative combinations capable of reshaping survival trajectories and patient quality of life.

Beyond survival metrics, the patient experience and adverse event profiles weigh heavily in assessing clinical utility. Combining immunotherapy with chemotherapy necessitates vigilance for immune-related toxicities and overlapping side effects. The trial’s rigorous monitoring ensures that therapeutic gains are not offset by intolerable toxicity, balancing efficacy with safety—a cornerstone of modern cancer care.

Should the combination of tislelizumab and capecitabine demonstrate improved recurrence-free and overall survival without disproportionate adverse events, it could redefine adjuvant treatment guidelines worldwide. Moreover, identifying molecular biomarkers predictive of response could personalize therapy, sparing non-responders from unnecessary toxicity and financial burden, while optimizing outcomes for those most likely to benefit.

The implications of this trial extend beyond BTC, highlighting the transformative potential of integrating immunotherapy into adjuvant protocols for other solid tumors with high relapse rates. Success could catalyze a paradigm shift, leveraging immune modulation to consolidate surgical cure and changing the natural history of aggressive malignancies.

Finally, the trial’s multidisciplinary approach—encompassing surgical oncology, medical oncology, molecular biology, and bioinformatics—exemplifies the collaborative spirit essential for tackling complex cancers. Through this synergy, new therapeutic frontiers open, driven by robust clinical evidence and a vision for improved patient survival.

As results from this pivotal trial emerge in coming years, the oncology community awaits with optimism. The hope is not only to extend survival for patients with resectable biliary tract cancers but to inspire a new chapter in the convergence of chemotherapy and immunotherapy—a powerful alliance against cancer’s resilience.

—

Subject of Research: Efficacy and safety of combining tislelizumab with capecitabine as adjuvant therapy in resectable biliary tract cancers

Article Title: Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial

Article References:
Wei, X., Jiang, Y., Zhou, J. et al. Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial. BMC Cancer 25, 938 (2025). https://doi.org/10.1186/s12885-025-14367-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14367-7